Atripla (Efavirenz/Tenofovir/FTC)
| Brand Name: |
Atripla |
| Generic Name: |
Efavirenz/ tenofovir/ emtricitabine, EFV/TDF/FTC |
| Adult Single Dose: |
One tablet containing 600 mg efavirenz, 300 mg tenofovir and 200 mg FTC |
| Food & Liquid Restrictions: |
Take on an empty stomach |
| Drug Class: |
1 NNRTI + 2 NRTIs |
The Basics
News
 HIV Meds and False Positives on Drug Tests: A Video Blog by Aaron Laxton (February 11, 2013)
"If you're on [Atripla] and you're going to have to do a drug screen ... you need to let the tester know whenever they do your drug screen whatever medications you're on. ... It's not the end of the world, but it's definitely something you need to know about."
From TheBody.com
 Antiretroviral Rounds: Resistance on Two Fronts (November 2, 2012)
From Journal Watch
On TheBodyPRO.com
- Switching From Atripla to Complera (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Complera and Atripla News (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
- Atripla's Co-Pay Program Now Saves More Money (September/October 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm? (Feb. 19, 2010; 3:39 p.m. Pacific Time)
A blog entry from CROI 2010 by Gerald Pierone Jr., M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Atripla Label Update Reflects New Efficacy, Safety and Resistance Data in Treatment Experienced Patients (January 7, 2010)
From U.S. Food and Drug Administration
- Australia: New HIV Drug Added to Taxpayer-Subsidized List (January 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Approval for Once-A-Day HIV Pill (December 17, 2007)
In BBC News Online, from BBC News
VIEW ALL ARTICLES
Research
- Sustiva, Atripla Tied to Neurologic Toxicity (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- 20% People Switch Atripla Due to Efavirenz Side Effects: Late Switches Are Common (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study (March 7, 2012)
Quad currently under review for marketing approval by U.S. and European regulatory agencies.
From Gilead Sciences, Inc.
On TheBodyPRO.com
- Switch to HIV Combo Pill May Improve Lipids (September 15, 2010)
From MedPage Today
- Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla (September 15, 2010)
From National AIDS Treatment Advocacy Project
- "Quad" Tablet vs. Atripla; GS 9350 (Cobicistat) vs. Ritonavir (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- QUAD Four-in-One Pill as Strong as Atripla, but a Kidney Concern Arises (February 18, 2010)
From National AIDS Treatment Advocacy Project
- Study Shows People Can Safely Switch to Atripla (December 2008)
To read PDF, click here.
From Project Inform
On TheBodyPRO.com
|
|
Advertisement
|
Email
Glossary
